Novel anti-obesity drugs and plasma lipids

作者：Nikolic Dragana; Toth Peter P; Ferlita Alessandra; Di Bartolo Vittoria; Montalto Giuseppe; Banach Maciej; Rizzo Manfredi^*

来源：Clinical Lipidology, 2014, 9(2): 179-187.

DOI：10.2217/CLP.14.7

• anti-obesity drugs
• contrave
• dyslipidemia
• lorcaserin
• low-density lipoprotein
• obesity
• Qsymia (R)
• triglyceride

Obesity is a health problem of global, epidemic proportions and a major risk factor for chronic diseases resulting in accelerated morbidity and mortality. Dyslipidemia with a predominance of small dense LDL, impaired functionality of HDL particles, and increased serum levels of remnant particles due to impaired clearance of triglyceride-rich lipoproteins significantly heightens cardiovascular events in obese subjects. Pharmacotherapy in combination with lifestyle modification is the primary approach to reduce obesity-related cardiovascular risk. Although there are several potential anti-obesity drugs, orlistat is the only agent that remains available in the market. Lorcaserin and Qsymia (R), approved by the US FDA last year, and contrave with potential approval in 2014, are new anti-obesity drugs with promising therapeutic effects. Although these drugs can be associated with adverse side effects, these agents have favorable effects on lipid profiles. However, the need for safer anti-obesity agents is clear.

• 出版日期2014-4